Zoetis Inc. $ZTS Shares Acquired by Krilogy Financial LLC

Krilogy Financial LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 55.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,536 shares of the company’s stock after buying an additional 9,798 shares during the period. Krilogy Financial LLC’s holdings in Zoetis were worth $4,029,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Savvy Advisors Inc. increased its position in shares of Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after purchasing an additional 1,114 shares during the period. Chicago Partners Investment Group LLC lifted its holdings in Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock valued at $750,000 after acquiring an additional 1,961 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Zoetis by 10.0% during the 2nd quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock valued at $368,245,000 after purchasing an additional 214,889 shares in the last quarter. Finally, Ninety One UK Ltd grew its stake in shares of Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after purchasing an additional 183,686 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 0.7%

NYSE:ZTS opened at $128.13 on Wednesday. The business’s fifty day moving average price is $124.03 and its 200 day moving average price is $135.84. The firm has a market capitalization of $56.47 billion, a price-to-earnings ratio of 21.57, a PEG ratio of 2.20 and a beta of 0.96. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ZTS shares. UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. Barclays started coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Finally, Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $152.45.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.